

Rigel to Present at Jefferies 2016 London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16th at 11:20am GMT.

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company completed and reported results from two Phase 3 clinical studies of fostamatinib in chronic immune thrombocytopenia (ITP) in August and October 2016. Rigel is also conducting Phase 2 clinical trials with fostamatinib in autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN) with fostamatinib. In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

Contact: Raul Rodriguez Phone: 650.624.1302 Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc.

Phone: 650.430.3777 Email: susan@rivily.com

Logo - https://photos.prnewswire.com/prnh/20030226/RIGLLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-

<u>releases/rigel-to-present-at-jefferies-2016-london-healthcare-conference-300360259.html</u> SOURCE Rigel Pharmaceuticals, Inc.